Innovative therapeutic approaches focused on CHI3L1, including small-molecule inhibitors and neutralizing antibodies, have displayed significant potential in preclinical research, effectively diminishing neuroinflammation, lowering amyloid plaque buildup, and enhancing neuronal survivability, along with neural stem cell recovery [77,239,240,241]. This evidence concerns the gene CHI3L1 and amyloidosis.